Human antibody specific for interleukin-1 alpha
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
1. A monoclonal antibody having a heavy chain comprising the amino acid residues 20-471 of SEQ ID NO: 9 and a light chain comprising the amino acid residues 23-236 of SEQ ID NO: 11.
2. A pharmaceutical composition comprising the monoclonal antibody of claim 1 .
3. A method of inhibiting migration of a human cell through a basement membrane matrix in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 2 .
4. A host cell expressing the monoclonal antibody of claim 1 .
5. A method of killing a cell expressing human IL-1 alpha, comprising contacting the cell with the monoclonal antibody of claim 1 .
6. A method of increasing Intercellular Adhesion Molecule 1 (ICAM1) and E-Selectin expression in human endothelial cells, comprising contacting the human endothelial cells with the monoclonal antibody of claim 1 .
7. A monoclonal antibody having a heavy chain consisting of the amino acid residues 20-471 of SEQ ID NO: 9 and a light chain consisting of the amino acid residues 23-236 of SEQ ID NO: 11.
8. A pharmaceutical composition comprising the monoclonal antibody of claim 7 .
9. A method of inhibiting migration of a human cell through a basement membrane matrix in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 8 .
10. A host cell expressing the monoclonal antibody of claim 7 .
11. A method of killing a cell expressing human IL-1 alpha, comprising contacting the cell with the monoclonal antibody of claim 7 .
12. A method of increasing Intercellular Adhesion Molecule 1 (ICAM1) and E-Selectin expression in human endothelial cells, comprising contacting the human endothelial cells with the monoclonal antibody of claim 7 .